Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Conflict of interest br Acknowledgements We would like to
2024-02-19

Conflict of interest Acknowledgements We would like to thank Editage (www.editage.jp) for English language editing. This work was supported by Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Grant Number 24592576. Co-existence of β- and β-adrenergic recept
-
To our knowledge BAY has not progressed to clinical developm
2024-02-19

To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit
-
Tension within the network could be
2024-02-19

Tension within the network could be explained by two potential mechanisms: the more classical contractility that is dependent on motor proteins that are pulling STA-21 filaments towards each other [10]; or contractility that is caused by disassembly of a crosslinked network of actin filaments [2].
-
br Difference between ACh and ER
2024-02-19

Difference between ACh and ER tests There are few reports concerning the provoked spasm between ER and ACh in the same patients [51], [52], [53]. Different mediators may have the potential of different coronary responses. In our experience, spasm provoked by intracoronary injection of ER is focal
-
The structures of these compounds were confirmed from
2024-02-19

The structures of these compounds were confirmed from their spectral and micro analytical data. Based on [M + H] 367, molecular formula of was established as CHON. The IR spectrum of showed coelenterazine due to CO stretching at 1700 Cm & OH stretching at 3188 Cm indicating that compound contains
-
br There are three types of HT receptors HT
2024-02-19

There are three types of 5-HT2 receptors. 5-HT2A, 5-HT2B and 5-HT2C receptors Exhibit 46–50% overall sequence identity and couple preferentially to Gq/11 to increase inositol phosphates and cytosolic [Ca2+] and in agreement with their long known role in muscle contraction and stimulation in the br
-
The molecular mechanisms involved in the pathogenesis of cho
2024-02-19

The molecular mechanisms involved in the pathogenesis of cholestatic pruritus remain unknown [45], [46]. Indeed, there has been an enormous effort at understanding the etiology of PBC-related pruritus, including work at the cellular and molecular level, but such efforts have not been translated into
-
br Introduction Lipoxygenases LOXs are a heterogeneous famil
2024-02-19

Introduction Lipoxygenases (LOXs) are a heterogeneous family of enzymes that catalyze the peroxidation of polyunsaturated fatty acids (PUFAs). By oxidizing free PUFAs, they were shown to contribute to the generation of various bioactive lipid mediators. However, LOX-mediated oxidation of PUFAs es
-
br Introduction Hepatocellular carcinoma HCC is an aggressiv
2024-02-19

Introduction Hepatocellular carcinoma (HCC) is an aggressive and malignant cancer detected in clinical practice, as it is the third key reason of tumor-related deaths worldwide, with > 800, 000 mortalities every year (Torre et al., 2015). Current treatments for HCC are surgical therapy, liver tra
-
br Eprosartan The AT R antagonist
2024-02-18

Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential Nifedipine and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, ind
-
Evidence from basic science studies suggests that
2024-02-18

Evidence from basic science studies suggests that Cd may play a role in prostate cancer through disruption of the androgen receptor (AR). AR, a hormone-activated transcription factor, is the key driver of prostate cancer progression [6]. Ironically, the AR is also required for normal prostate growth
-
EGTA br Results br Discussion Here we uncovered a role for
2024-02-18

Results Discussion Here, we uncovered a role for Wnt-Fz7 signaling in LTP-dependent spine plasticity and synaptic localization of AMPARs. We demonstrated that LTP induction increased Wnt7a/b protein at EGTA and spines. Direct blockade of endogenous Wnts impaired LTP-mediated structural spine p
-
br Comparison to IWG In addition to
2024-02-18

Comparison to IWG In addition to the NIA AA, the other group that has established diagnostic guidelines for AD that incorporate biomarkers is the IWG [64,74,75]. In the most recent formal IWG document, published in 2014 [75], the diagnosis of AD required the presence of cognitive symptoms plus an
-
In conclusion phenolic hydroxyl was introduced
2024-02-18

In conclusion, phenolic hydroxyl was introduced not only to C3 side chain but also to C6 or C7 position of the quinoxalinone core, resulting in a new group of ARIs candidates exhibiting antioxidant activity. Biological activity tests suggested that compounds were not only sufficient to inhibit ALR2
-
gamma secretase inhibitor It thus appeared reasonable that A
2024-02-18

It thus appeared reasonable that AR needed to be inhibited and great experimental efforts began which are still on-going [6]. Indeed, hundreds of ARIs have been characterized but no significant drug development has followed. The case of Sorbinil, which did not pass clinical trials is emblematic [7]
16594 records 212/1107 page Previous Next First page 上5页 211212213214215 下5页 Last page